ASCO GU 2019: Atezolizumab and bevacizumab in non-clear cell kidney cancer and sarcomatoid kidney cancer

Results from this trial for patients with non-clear cell renal cell carcinoma (RCC) or sarcomatoid RCC were reported at the American Society of Clinical Oncology (ASCO) genitourinary (GU) conference held in San Francisco in February 2019. The combination of atezolizumab and bevacizumab has been shown to be effective in the treatment of clear cell RCC. […]

read more

ASCO GU 2019: Gemcitabine plus axitinib in patients with sarcomatoid renal cell carcinoma (RCC)

Results from this trial for sarcomatoid renal cell carcinoma (RCC) patients were reported at the American Society of Clinical Oncology (ASCO) genitourinary (GU) conference held in San Francisco in February 2019. Because there are limited treatment options for this aggressive form of RCC, the trial was designed to verify anecdotal reports of good responders to […]

read more

An overview of the management of rare subtypes of kidney cancer

This interview with Dr Ramaprasad Srinivasan from the National Cancer Institute in Bethesda, USA, discusses the management of sarcomatoid renal cell carcinoma (RCC), papillary RCC, and hereditary RCC, such as hereditary leiomyomatosis RCC (HLRCC). Watch the interview with Dr Srinivasan on Practice Update here

read more
Showing 21 to 23 of 23 results
  TOP